[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515282":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":58,"collaborators":12,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":12,"enrollmentInfo":70,"targetDuration":12,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":41,"whyStopped":12,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Arm","NO_INTERVENTION","The control arm will receive standard treatment.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Interventional Arm","EXPERIMENTAL","Individuals within the intervention will receive standard care and access to the Breast Cancer Treatment Application (BCTA) for 13 months.",[18],"Other: At-home Breast Oncology care Delivered with E-health solutions - ABODE",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"At-home Breast Oncology care Delivered with E-health solutions - ABODE","The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.",[14],[25],{"name":26,"affiliation":5,"role":27},"Tulin Cil, MD, MEd","PRINCIPAL_INVESTIGATOR",[29,34],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","416-946-4507","3984","tulin.cil@uhn.ca",{"name":35,"role":30,"phone":36,"phoneExt":12,"email":37},"Emma Reel, MSW","647-202-1028","emma.reel@uhn.ca",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Tulin Cil","RECRUITING","Toronto","Ontario","M5G2M9","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-79.39864,43.70643,{"lat":51,"lon":50},[54,56],{"name":26,"role":30,"phone":55,"phoneExt":12,"email":33},"4169464507",{"name":35,"role":30,"phone":57,"phoneExt":12,"email":37},"6472021028",{"type":59,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100515282","at-home-breast-oncology-care-delivered-with-e-health-solutions-100515282",false,"NCT05989477","At-home Breast Oncology Care Delivered With E-health Solutions","At-home Breast Oncology Care Delivered With E-health Solutions The ABODE Study","ABODE","Inclusion Criteria:\n\n* Females (assigned female at birth)\\*\n* Diagnosed with first, primary invasive BC\n* Must have surgery as their first step in treatment pathway\n* Age≥18\n* Access to an electronic device with connection to the internet\n* A valid email address\n* Can communicate in English \\*Since BC risk is sex-related and based on physiological values, our inclusion criteria are based on sex (not gender)\n\nExclusion criteria:\n\n* Males (assigned male at birth), as BC surgical treatment options and experiences are different\n* Diagnosed with non-operable breast cancer\n* Stage 4\u002Fmetastatic (whether determined at diagnosis or during surgery)\n* Those with hearing or visual challenges\n* Neo-adjuvant chemotherapy\n* Should not be enrolled in any other UHN study using an e-Health application\n* Breast cancer surgery is scheduled for less 5 business days after enrollment","FEMALE","18 Years",{"count":71,"type":72},200,"ESTIMATED","INTERVENTIONAL",[75],"NA","The COVID-19 pandemic has significantly impacted healthcare service delivery, highlighting the need for high quality virtual patient care. Our team has developed a multi-dimensional remote eHealth solution for newly diagnosed breast cancer patients and their practitioners to use during the diagnostic and follow-up period. The ABODE study involved development of a Breast Cancer Treatment Application (app) which will facilitate virtual consultations, deliver patient education material, and collect patient reported outcome measures (PROMs). Using a randomized controlled trial design, the team will evaluate a variety of outcomes for breast cancer patients who will use the app throughout their diagnosis and treatment period.\n\nPrimary Objective: To compare changes in patient activation (assessed by PAM-13) over 1 year among newly diagnosed breast cancer patients between those using the app and those receiving standard care.\n\nSecondary Objectives:\n\n1. Compare additional PROMs between the standard care and intervention groups\n2. Describe health service outcomes among app users\n3. Explore end-user experience of using the app\n4. Measure activity levels using wearable devices",[78,79,80],"Patient Engagement","Patient Activation","Patient Reported Outcome Measures",[82,83,84,85,86,87],"e-Health","m-Health","Mobile Application","Psychosocial Oncology","Survivorship","Breast Cancer","2025-04-11",{"date":90,"type":91},"2025-04-16","ACTUAL",{"date":93,"type":91},"2023-06-22",{"date":95,"type":72},"2026-06-22",{"name":5,"class":6},1]